:. H. Muret;-clermont-ferrand, O. Laurichesse, M. Lesens, N. Vidal, and C. Mrozek,

O. Aumeran, V. Baud, P. Corbin, S. Letertre, J. Casanova et al.,

:. B. Guadeloupe, I. Hoen, I. Lamaury, E. Fabre, R. Curlier et al.,

L. Roche-sur-yon, :. D. Merrien, P. Perré, T. Guimard, O. Bollangier et al.,

;. C. Marseille, M. Dhiver, A. Mokhtari, H. Ménard, C. Dupont et al.,

M. Sainte-marguerite, :. S. Brégigeon, O. Zaegel-faucher, V. Obry-roguet, H. Laroche et al.,

:. N. Montpellier, V. L. Atoui, A. Moing, N. Makinson, C. Meftah et al.,

:. P. Nice, S. Pugliese, C. Breaud, J. Ceppi, E. Courjon et al.,

;. R. Paris, V. Landman, C. Joly, S. Rioux, A. Lariven et al.,

G. Consigny, P. Cessot, J. Bossi, J. Goesch, G. Gilquin et al.,

;. M. Paris, F. Valantin, R. Caby, R. Tubiana, S. Agher et al., All members of DAT'AIDS group gave their consent to be listed. Funding No funding was obtained for this study, 2017.

D. F. Éditorial, Contrôler durablement l'épidémie VIH en France, Bull Epidémiol Hebd, vol.18, pp.346-353, 2017.

A. J. Gourlay, A. M. Pharris, T. Noori, V. Supervie, M. Rosinska et al., Towards standardized definitions for monitoring the continuum of HIV care in Europe, AIDS Lond Engl, vol.31, pp.2053-2061, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01590423

M. T. Levasseur, N. D. Goldstein, L. P. Tabb, B. L. Olivieri-mui, and S. L. Welles, The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices, J Acquir Immune Defic Syndr, vol.77, pp.31-40, 1999.

A. , ANSM établit la RTU de Truvada dans la prophylaxie pré-exposition au VIH -Point d'information, 2015.

, La prophylaxie pré-exposition (PrEP) au VIH par TRUVADA, HAS, 2017.

P. Morlat, A. France, ). , F. Sida, and F. , Prise en charge médicale des personnes vivant avec le VIH: rapport, 2013.

. Ansm, Truvada dans la prophylaxie Pré-exposition (PrEP) au VIH : fin de la Recommandation Temporaire d'Utilisation -Informations importantes concernant le bon usage de Truvada® dans l'indication « Prophylaxie préexposition (PrEP) » au VIH -Brochure destinée aux prescripteurs, 2017.

F. Lot, F. Cazein, N. Ndeikoundam, J. Pillonel, C. Pioche et al., Infection par le VIH et IST bactériennes, Inst Veille Sanit Santé Publique Fr, vol.26, 2018.

P. Pugliese, L. Cuzin, A. Cabié, I. Poizot-martin, C. Allavena et al., A large French prospective cohort of HIV-infected patients: the Nadis cohort, HIV Med, vol.10, pp.504-515, 2009.

D. K. Smith, M. Chang, W. A. Duffus, S. Okoye, and S. Weissman, Missed opportunities to prescribe Preexposure prophylaxis in South Carolina, Clin Infect Dis Off Publ Infect Dis Soc Am, pp.2013-2016, 2018.

A. E. Brown, H. Mohammed, D. Ogaz, P. D. Kirwan, M. Yung et al., Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)?, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, vol.22, 2017.

Y. Jia, M. H. Aliyu, J. Huang, and Z. , Dynamics of the HIV epidemic in MSM, Biomed Res Int, p.497543, 2014.

V. Mrav?ík, M. Pito?ák, R. Hejzák, B. Janíková, and I. Procházka, HIV epidemic among men who have sex with men in the Czech Republic, 2016: high time for targeted action, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, vol.22, 2017.

S. Stahlman, C. Lyons, P. S. Sullivan, K. H. Mayer, S. Hosein et al., HIV incidence among gay men and other men who have sex with men in 2020: where is the epidemic heading? Sex Health, vol.14, pp.5-17, 2017.

J. Sewell, V. Cambiano, A. Miltz, A. Speakman, F. C. Lampe et al., Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, Sex Transm Infect, pp.2013-2016, 2018.

J. Frankis, P. Flowers, L. Mcdaid, and A. Bourne, Low levels of chemsex among men who have sex with men, but high levels of risk among men who engage in chemsex: analysis of a cross-sectional online survey across four countries, Sex Health, vol.15, pp.144-50, 2018.

A. González-baeza, H. Dolengevich-segal, I. Pérez-valero, A. Cabello, M. J. Téllez et al., Sexualized drug use (Chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 study, AIDS Patient Care STDs, vol.32, pp.112-120, 2018.

M. Pakianathan, W. Whittaker, M. J. Lee, J. Avery, S. Green et al., Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics, HIV Med, 2018.

M. Bracchi, D. Stuart, R. Castles, S. Khoo, D. Back et al., Increasing use of "party drugs" in people living with HIV on antiretrovirals: a concern for patient safety, AIDS Lond Engl, vol.29, pp.1585-92, 2015.

O. Staltari, C. Leporini, B. Caroleo, E. Russo, A. Siniscalchi et al., Drug-drug interactions: antiretroviral drugs and recreational drugs, Recent Patents CNS Drug Discov, vol.9, pp.153-63, 2014.

C. Baecke, I. C. Gyssens, L. Decoutere, J. Van-der-hilst, and P. Messiaen, Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study, Neth J Med, vol.75, pp.235-275, 2017.

N. Kojima, D. J. Davey, and J. D. Klausner, Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men, AIDS Lond Engl, vol.30, pp.2251-2253, 2016.

A. Y. Liu, S. E. Cohen, E. Vittinghoff, P. L. Anderson, S. Doblecki-lewis et al., Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services, JAMA Intern Med, vol.176, pp.75-84, 2016.

V. Nguyen, Z. R. Greenwald, H. Trottier, M. Cadieux, A. Goyette et al., Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV, AIDS Lond Engl, vol.32, pp.523-553, 2018.

H. M. Scott and J. D. Klausner, Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US, AIDS Res Ther, vol.13, p.5, 2016.

M. Malahleha, K. Ahmed, J. Deese, K. Nanda, L. Van-damme et al., Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report, J Med Case Rep, vol.9, p.207, 2015.

M. M. Solomon, M. Schechter, A. Y. Liu, V. M. Mcmahan, J. V. Guanira et al., The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B, J Acquir Immune Defic Syndr, vol.71, pp.281-286, 1999.

E. Wright, A. Grulich, K. Roy, M. Boyd, V. Cornelisse et al., Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Update, J Virus Erad, vol.4, pp.143-59, 2018.

E. L. Ross, S. K. Cinti, and D. W. Hutton, Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men, J Acquir Immune Defic Syndr, vol.72, pp.61-67, 1999.

, ANSM. Suivi de l'utilisation de Truvada® ou génériques pour une prophylaxie pré-exposition (PrEP) au VIH à partir du SNIIRAM, 2018.

S. Baral, C. H. Logie, A. Grosso, A. L. Wirtz, and C. Beyrer, Modified social ecological model: a tool to guide the assessment of the risks and risk contexts of HIV epidemics, BMC Public Health, vol.13, p.482, 2013.

K. Champenois, A. Cousien, L. Cuzin, L. Vu, S. Deuffic-burban et al., Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study, BMC Infect Dis, vol.13, 0200.
URL : https://hal.archives-ouvertes.fr/inserm-00822062

M. Taborelli, S. Virdone, L. Camoni, R. V. Zucchetto, A. Frova et al., The persistent problem of late HIV diagnosis in people with AIDS: a populationbased study in Italy, Public Health, vol.142, pp.39-45, 2017.

K. E. Darling, A. Hachfeld, M. Cavassini, O. Kirk, H. Furrer et al., Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better, Swiss Med Wkly, vol.146, p.14348, 2016.

S. O'connell, J. Enkelmann, C. Sadlier, and C. Bergin, Late HIV presentationmissed opportunities and factors associated with a changing pattern over time, Int J STD AIDS, vol.28, pp.814-835, 2017.

R. Grant, A. Liu, J. Hecht, S. Buchbinder, S. Weber et al., Scale-up of Preexposure prophylaxis in San Francisco to impact HIV incidence, 2015.